|
|
Volumn 4, Issue 1, 2005, Pages 11-12
|
|
Rheumatoid arthritis market
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ACETYLSALICYLIC ACID;
ADALIMUMAB;
ANTIMALARIAL AGENT;
ATLIZUMAB;
CERTOLIZUMAB PEGOL;
CORTICOSTEROID;
CYCLOOXYGENASE 2 INHIBITOR;
CYCLOSPORIN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
ETANERCEPT;
GENERIC DRUG;
GOLD SALT;
INFLIXIMAB;
INTERLEUKIN 6 RECEPTOR ANTIBODY;
LEFLUNOMIDE;
LUMIRACOXIB;
METHOTREXATE;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
RECEPTOR ANTIBODY;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RITUXIMAB;
ROFECOXIB;
SALAZOSULFAPYRIDINE;
SCIO 469;
STEROID;
TEMSIROLIMUS;
TETRACYCLINE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANTIINFLAMMATORY ACTIVITY;
AUTOIMMUNITY;
CARDIOVASCULAR DISEASE;
DISEASE SEVERITY;
DRUG MARKETING;
DRUG MECHANISM;
HUMAN;
JOINT DESTRUCTION;
NOTE;
PRESCRIPTION;
PRIORITY JOURNAL;
PROGNOSIS;
QUALITY OF LIFE;
RHEUMATOID ARTHRITIS;
SIDE EFFECT;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DRUG INDUSTRY;
GREAT BRITAIN;
HEALTH CARE SECTOR;
HUMANS;
TIME FACTORS;
|
|
EID: 12144250200
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd1611 Document Type: Note |
|
Times cited : (27)
|
|
References (0)
|
